Categories Uncategorized

New Research Discovers Connection Between Psychedelic Experiences, Personality Traits

Psychedelic drugs such as LSD and psilocybin mushrooms are known to cause various effects on different people; those effects range from encounters with entities from out of this world to complete dissolution from the ego. The unique nature of these experiences makes it rather hard for researchers to make definite conclusions concerning the end results of indulging in these psychedelic substances.

However, new research shows that there may be a way to forecast how an individual will respond to psychedelics based on a person’s personality. Psychiatrists originally discovered a link between psychedelic drug-related experiences and an individual’s personality structure in the early stages of psychedelic research years ago.

In an effort to learn more and add to these findings, University of Bergen’s Petter Grahl Johnstad recently published a study in the “Journal of Psychoactive Drugs.” The paper calls attention to various connections between subjective responses to these mind-altering substances and an individual’s personality traits.

To carry out the study, Johnstad evaluated the personalities of 319 individuals who used psychedelics. He did this using two questionnaires that had been developed to focus on specific elements of an individual’s nature. One of these, the TIPI or Ten-Item Personality Inventory, measures the big five personality traits, which include openness, extraversion, emotional stability, conscientiousness and agreeableness.

Additionally, study participants were asked to fill out a Risk Taking Index, which assesses an individual’s tendency to engage in risky behaviors. The results from both questionnaires were then corresponded to participants’ reports on their experiences with psychedelics. The purpose of this was to determine the effect a participant’s personality traits might have upon psychedelic trips.

The results showed that individuals who used psychedelics tended to have an above-average score on the TIPI test as well as for risk taking. This suggests that an individual’s motive for using psychedelic substances may be driven by their genetic make-up. The participants’ test scores also affected the nature of each participant’s drug-induced trip.

While on psychedelics, individuals who were highly extroverted mostly discovered a deeper sense of connection to other individuals and were unlikely to encounter otherworldly beings. The researchers hypothesize that this reflects the individual’s preference to socially interact with others as opposed to exploring their own psyche.

Those who recorded high-openness levels were more likely to come into contact with transcendent forces and unearthly beings as well as experience inner visions or love. Johnstad and other researchers theorize that the open mindedness and curiosity of such individuals may prompt them to pursue intense and unusual experiences. Additionally, individuals who had high levels of emotional stability were less likely to feel fear when they were high.

There’s still a lot to learn about psychedelics substances, and many companies are positioning themselves to utilize the emerging research about this class of substances. For example, Pure Extracts Technologies Inc. (CSE: PULL) looks set to be a leader in the swift development of functional mushroom products and psychedelic-based medicines.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…

19 hours ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

4 months ago